Global Oral Antidiabetic Drugs Market Insights and Forecast to 2027

Diabetes mellitus is a group of a metabolic disorder caused when the body is unable to produce required quantity of Insulin. Insulin is a hormone secreted by beta cells of the islet of Langerhans of the pancreas. Various symptoms associated with diabetes disorder include recurrent urination, increased thirst, and hunger. Diabetes can cause much chronic complication if left untreated. Some of them include acute complications like diabetic ketoacidosis, chronic kidney failure, foot ulcers, and damage to the eyes.

Market Analysis and Insights: Global Oral Antidiabetic Drugs Market
The global Oral Antidiabetic Drugs market is valued at US$ XX million in 2019. The market size will reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.

Global Oral Antidiabetic Drugs Scope and Market Size
Oral Antidiabetic Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Oral Antidiabetic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Sulfonylureas
Meglitinides
Alpha-glucosidase inhibitors

Segment by Application
Hospitals
Clinics
Others

By Company
Eli Lilly
Abbott
Biocon
Sanofi
Sunpharma
Novartis
Novo Nordisk
Merck
Pfizer

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia

Frequently Asked Questions